2 Information about pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel

2 Information about pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, Merck Sharp & Dohme) plus carboplatin and paclitaxel or nab-paclitaxel is indicated for 'the first-line treatment of metastatic squamous non-small-cell lung carcinoma in adults'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

Price

2.3 Pembrolizumab solution for infusion costs £2,630 per 100‑mg vial (excluding VAT; BNF online, accessed August 2021).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)